By playing, you agree to uListen's Terms and Privacy Policy and YouTube's Terms of Service.

Big Ideas in 2024: Democratizing “Miracle Drugs” with Julie Yoo

In 2023, a wave of therapies hailed as miracle drugs — including GLP-1’s and curative cell and gene therapies — had a profound impact in patients’ lives. With 3.6 million prescription claims for GLP-1s in 2022, the question arises: Can innovators establish a sustainable approach to bring these groundbreaking drugs to market without causing financial strain or system breakdown? Julie Yoo, General Partner at Andreessen Horowitz, shares a compelling big idea for 2024: Democratizing “Miracle Drugs”. Timecodes: 00:00 - Big Ideas in Tech 2024 01:39 - Democratizing “Miracle Drugs” 02:35 - How a GPL-1 works and the potential impact of the drug 08:32 - Curative cell and gene therapies 11:21 - Drug costs and insurance systems 15:16 -The changes needed to enable drug access 17:36 - What solutions are being built? 20:48 - Policy, the FDA, and CMS Resources: View all 40+ big ideas: https://a16z.com/bigideas2024 Find Julie on X: https://twitter.com/julesyoo Stay Updated: Find a16z on Twitter: https://twitter.com/a16z Find a16z on LinkedIn: https://www.linkedin.com/company/a16z Subscribe on your favorite podcast app: https://a16z.simplecast.com/ Follow our host: https://twitter.com/stephsmithio Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.

Steph SmithhostJulie Yooguest

Dec 11, 202323mWatch on YouTube ↗

Summaries, chapters, transcripts, and FAQs on this page are made by uListen, not YouTube.

EPISODE INFO

Released: December 11, 2023
Duration: 23m
Channel: a16z
Watch on YouTube: ▶ Open ↗

EPISODE DESCRIPTION

In 2023, a wave of therapies hailed as miracle drugs — including GLP-1’s and curative cell and gene therapies — had a profound impact in patients’ lives. With 3.6 million prescription claims for GLP-1s in 2022, the question arises: Can innovators establish a sustainable approach to bring these groundbreaking drugs to market without causing financial strain or system breakdown? Julie Yoo, General Partner at Andreessen Horowitz, shares a compelling big idea for 2024: Democratizing “Miracle Drugs”. Timecodes: 00:00 - Big Ideas in Tech 2024 01:39 - Democratizing “Miracle Drugs” 02:35 - How a GPL-1 works and the potential impact of the drug 08:32 - Curative cell and gene therapies 11:21 - Drug costs and insurance systems 15:16 -The changes needed to enable drug access 17:36 - What solutions are being built? 20:48 - Policy, the FDA, and CMS Resources: View all 40+ big ideas: https://a16z.com/bigideas2024 Find Julie on X: https://twitter.com/julesyoo Stay Updated: Find a16z on Twitter: https://twitter.com/a16z Find a16z on LinkedIn: https://www.linkedin.com/company/a16z Subscribe on your favorite podcast app: https://a16z.simplecast.com/ Follow our host: https://twitter.com/stephsmithio Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.

SPEAKERS

Steph Smith
host
Host/interviewer for the a16z “Big Ideas in 2024” series.
Julie Yoo
guest
General Partner on Andreessen Horowitz’s Bio + Health team.

EPISODE SUMMARY

In this episode of a16z, featuring Steph Smith and Julie Yoo, Big Ideas in 2024: Democratizing “Miracle Drugs” with Julie Yoo explores julie Yoo on Making Miracle Drugs Affordable Without Breaking Healthcare Julie Yoo argues that GLP-1s and curative cell and gene therapies are miracle drugs, but the current insurance system cannot bear their costs or properly value them.

RELATED EPISODES